Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
Key Highlights
- ➤Eloxx appoints Geno Germano to its Board of Directors, effective October 19, 2026
- ➤Germano brings more than 35 years of biopharmaceutical development and commercialization experience
- ➤Germano previously led Pfizer’s approximately $14 billion Global Innovative Pharmaceutical portfolio
- ➤Exaluren targets rare kidney diseases including nonsense mutation Alport syndrome and ADPKD
- ➤Eloxx exclusively licensed ZKN-013 to Almirall for rare dermatological diseases
Expert Statements
Sumit Aggarwal, President and Chief Executive Officer of Eloxx Pharmaceuticals
“Geno is an accomplished biopharmaceutical leader whose experience developing and commercializing medicines at global scale, and guiding emerging companies through pivotal stages of growth, will be invaluable to Eloxx. We are delighted to welcome him to our Board.”
Geno Germano, Director of Eloxx Pharmaceuticals
“Eloxx is pursuing a differentiated approach to treating the underlying genetic cause of rare kidney diseases, and exaluren has the potential to make a meaningful difference for patients who currently have no approved therapies that address the root cause of their disease. I look forward to working with Sumit, the Board and the management team as the company advances its clinical programs.”
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors PR Newswire
* Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business * Extensive public company board experience, including current service as Chairman of Entera Bio and as a director of Precision BioSciences ARLINGTON, Mass., Oct. 19, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the appointment of Geno Germano to its Board of Directors, effective October 19, 2026.
Get started
Create a free account to read the full story.